Eden Research plc Director/PDMR Shareholding (7997G)

TIDMEDEN

RNS Number : 7997G

Eden Research plc

28 July 2021

28 July 2021

Eden Research plc

("Eden" or "Company")

Director/PDMR Shareholding

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, announces that Sean Smith, CEO, has purchased 180,000 shares in Eden at a price of GBP0.10 per share.

Following the transaction outlined above, Mr. Smith's interest in the share capital of the Company is 911,039 Ordinary Shares representing 0.24 per cent. of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

For further information contact:

 
                                                www.edenresearch.com 
   Eden Research plc 
 Sean Smith 
  Alex Abrey                                    01285 359 555 
 
   Cenkos Securities plc (Nominated advisor 
   and broker) 
 Giles Balleny / Camilla Hume/ Mark Connelly 
  (corporate finance) 
  Michael Johnson (sales)                       020 7397 8900 
 
   Hawthorn Advisors (Financial PR) 
 Lorna Cobbett / Victoria Ainsworth             [e-mail] 
 
 
 1    Details of the person discharging managerial responsibilities / person closely associated 
---  ----------------------------------------------------------------------------------------------- 
 a)   Name                                                           Sean Smith 
---  -------------------------------------------------------------  -------------------------------- 
 2    Reason for the notification 
---  ----------------------------------------------------------------------------------------------- 
 a)   Position/status                                                Chief Executive Officer 
---  -------------------------------------------------------------  -------------------------------- 
 b)   Initial notification /Amendment                                Initial Notification 
---  -------------------------------------------------------------  -------------------------------- 
 3    Details of the issuer, emission allowance market participant, auction platform, auctioneer 
       or auction monitor 
---  ----------------------------------------------------------------------------------------------- 
 a)   Name                                                           Eden Research plc 
---  -------------------------------------------------------------  -------------------------------- 
 b)   LEI                                                            213800ZWTYTVQQSM3J85 
---  -------------------------------------------------------------  -------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
---  ----------------------------------------------------------------------------------------------- 
 a)   Description of the financial instrument, type of instrument    Ordinary shares of 1 pence each 
       Identification code 
 
                                                                      GB0001646941 
---  -------------------------------------------------------------  -------------------------------- 
 b)   Nature of the transaction                                      Purchase of Ordinary Shares 
---  -------------------------------------------------------------  -------------------------------- 
 c)   Price(s) and volume(s)                                          Price(s)   Volume(s) 
                                                                      ---------  ---------- 
                                                                       10.00p     180,000 
                                                                      ---------  ---------- 
---  -------------------------------------------------------------  -------------------------------- 
 d)   Aggregated information 
       - Aggregated volume 
       - Price                                                         N/A 
---  -------------------------------------------------------------  -------------------------------- 
 e)   Date of the transaction                                        28 July 2021 
---  -------------------------------------------------------------  -------------------------------- 
 f)   Place of the transaction                                       LSE, AIM Market (XLON) 
---  -------------------------------------------------------------  -------------------------------- 
 

Notes to Editors:

Eden Research is an AIM quoted company that develops and supplies breakthrough biopesticide products and natural, plastic-free microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's Sustaine(R) encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally derived, plastic-free, biodegradable micro-spheres derived from yeast extract. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden has numerous patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. Eden was admitted to trading on AIM in May 2012.

For more information about Eden, please visit: www.edenresearch.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSEFFDAEFSEIW

(END) Dow Jones Newswires

July 28, 2021 09:53 ET (13:53 GMT)